Education
About Us
Working with TipRanks
Follow Us
Genetec Corp. (JP:4492)
:4492
Top Page
Genetec Corp.
(4492)
Rating:68Neutral
Price Target:
¥477.00
▲(5.76%Upside)
Genetec Corp. (4492) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥5.21B
Dividend Yield4.43%
Average Volume (3M)81.71K
Price to Earnings (P/E)12.0
Beta (1Y)0.96
Revenue Growth13.66%
EPS Growth1.12%
CountryJP
Employees347
SectorTechnology
Sector Strength79
IndustrySoftware - Application
Share Statistics
EPS (TTM)18.37
Shares Outstanding11,687,000
10 Day Avg. Volume26,250
30 Day Avg. Volume81,713
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)2.75
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Genetec Corp. Business Overview & Revenue Model
Company DescriptionGenetec Corp. (4492) is a leading biotechnology company that specializes in the development and commercialization of innovative genetic solutions. The company operates in the biotechnology sector, focusing on the research and development of genetic engineering technologies, including gene editing, gene therapy, and synthetic biology. Genetec Corp. aims to address critical healthcare challenges by providing advanced genetic technologies and services to improve human health and well-being.
How the Company Makes MoneyGenetec Corp. generates revenue primarily through the commercialization of its proprietary genetic technologies and solutions. The company earns money by licensing its technologies to pharmaceutical and biotechnology companies, allowing them to incorporate these innovations into their own product pipelines. Additionally, Genetec Corp. engages in strategic partnerships and collaborations with research institutions and healthcare organizations to co-develop new therapies and treatments, sharing the resulting revenues. The company may also receive funding through grants and government contracts aimed at advancing genetic research and application. Its earnings are further supplemented by offering consulting services and selling genetic testing kits directly to consumers or healthcare providers.
Genetec Corp. Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 8.04B | 7.15B | 5.86B | 4.68B | 4.08B | 4.72B | Gross Profit |
| 3.28B | 2.91B | 2.32B | 1.96B | 1.56B | 1.61B | EBIT |
| 754.19M | 629.43M | 105.88M | 190.09M | 254.16M | 336.00M | EBITDA |
| 857.30M | 783.24M | 245.09M | 153.83M | 301.93M | 356.00M | Net Income Common Stockholders |
| 426.69M | 414.77M | 23.76M | 56.64M | 173.41M | 212.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.43B | 1.17B | 1.08B | 1.04B | 1.48B | 1.12B | Total Assets |
| 4.52B | 4.52B | 4.12B | 3.25B | 2.84B | 2.69B | Total Debt |
| 1.09B | 640.00M | 976.09M | 50.62M | 75.00M | 165.00M | Net Debt |
| -343.00M | -528.08M | -99.69M | -994.23M | -1.41B | -958.00M | Total Liabilities |
| 2.33B | 2.31B | 2.26B | 1.39B | 1.02B | 1.05B | Stockholders Equity |
| 2.19B | 2.21B | 1.87B | 1.86B | 1.83B | 1.64B |
| Cash Flow | Free Cash Flow | ||||
| 0.00 | 495.19M | -359.44M | -176.37M | 406.28M | 51.90M | Operating Cash Flow |
| 0.00 | 602.37M | -223.12M | -24.03M | 443.26M | 61.30M | Investing Cash Flow |
| 0.00 | -55.73M | -439.20M | -98.15M | -38.53M | -49.39M | Financing Cash Flow |
| 0.00 | -410.02M | 714.93M | -94.71M | -76.04M | 403.57M |
Genetec Corp. Technical Analysis
Negative
451.00
Price Trends
480.08
Negative
507.30
Negative
542.87
Negative
Market Momentum
-10.58
Negative
38.33
Neutral
38.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4492, the sentiment is Negative. The current price of 451 is above the 20-day moving average (MA) of 443.55, below the 50-day MA of 480.08, and below the 200-day MA of 542.87, indicating a bearish trend. The MACD of -10.58 indicates Negative momentum. The RSI at 38.33 is Neutral, neither overbought nor oversold. The STOCH value of 38.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4492.
Genetec Corp. Peers Comparison
Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | ¥4.76B | 22.11 | 3.26% | 14.90% | -1.40% | ||
71 Outperform | ¥5.04B | 18.66 | 0.69% | 10.58% | 29.96% | ||
69 Neutral | ¥5.12B | 12.87 | 1.99% | 7.19% | -2.13% | ||
68 Neutral | ¥5.21B | 12.03 | 4.43% | 13.66% | 1.12% | ||
66 Neutral | ¥4.43B | 89.08 | 2.61% | -0.26% | -75.64% | ||
62 Neutral | $11.97B | 10.08 | -7.46% | 2.96% | 7.37% | -8.22% | |
47 Neutral | ¥5.72B | ― | ― | -3.01% | 95.93% |
* Technology Sector Average
Performance Comparison
JP:4492
Genetec Corp.
443.00
-172.49
-28.02%
JP:2321
Softfront Holdings
109.00
29.00
36.25%
JP:3841
Jedat Inc.
1,526.00
365.40
31.48%
JP:4060
rakumo Inc.
861.00
-235.62
-21.49%
JP:4491
Computer Management Co., Ltd.
2,515.00
891.12
54.88%
JP:4829
Nihon Enterprise Co., Ltd.
115.00
-18.63
-13.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.